Cargando…

2359. Prospective Feasibility Study for Novel Ultrasensitive Multiplexed Immunoassay for Clostridiodes difficile Toxins A and B

BACKGROUND: The diagnosis of Clostridiodes difficile infection is challenging. A wide array of diagnostic tests are used in practice; however, each available test has important limitations. We examined the feasibility and analytical performance of a novel ultrasensitive multiplexed immunoassay desig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Watson, Lauren, Zimbric, Michele L, Shaughnessy, Catherine, Kale, Shraddha, Debad, Jeff, Navaratnam, Manjula, Safdar, Nasia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810414/ http://dx.doi.org/10.1093/ofid/ofz360.2037

Ejemplares similares

1089. Analytical Performance of an Ultrasensitive Immunoassay for Detection of Clostridium difficile Toxins in Stool
por: Bartolome, Amelita, et al.
Publicado: (2018)

2379. It’s Getting Complicated: Outcomes of Clostridiodes difficile PCR Positive/Toxin-Negative Patients
por: Morillas, Jose A, et al.
Publicado: (2019)

Updates and Opinions in Diagnosis and Treatment of Clostridiodes difficile in Pediatrics
por: Malhotra, Sanchi, et al.
Publicado: (2021)

Risk for Clostridiodes difficile Infection among Older Adults with Cancer
por: Kamboj, Mini, et al.
Publicado: (2019)

972. Asymptomatic Carriage of Clostridiodes difficile and Risk of Subsequent Infection
por: Espiritu, Katrina, et al.
Publicado: (2018)

779. Clostridiodes difficile: Is it time for surveillance! Cost-benefit analysis
por: Yassin, Mohamed, et al.
Publicado: (2020)

A Predictive Model to Identify Complicated Clostridiodes difficile Infection
por: Berinstein, Jeffrey A, et al.
Publicado: (2023)

Fecal microbiota transplantation for patients on antibiotic treatment with C. difficile infection history (GRAFT): Study protocol for a phase II, randomized, double-blind, placebo-controlled trial to prevent recurrent C. difficile infections
por: Kates, Ashley E., et al.
Publicado: (2020)

PROJECT ADMINISTRATION AGREEMENT KN2359/BE
por: THE EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH, CERN, et al.
Publicado: (2014)

Descriptive Study of Gut Microbiota in Infected and Colonized Subjects by Clostridiodes difficile
por: Sánchez-Pellicer, Pedro, et al.
Publicado: (2021)

2393. Dimensions of Cumulative Antibiotic Exposure and Risk of Hospital Onset Clostridiodes Difficile
por: Song, Jiyoun, et al.
Publicado: (2019)

Management and characteristics of patients suffering from Clostridiodes difficile infection in primary care
por: Klezovich-Bénard, Maria, et al.
Publicado: (2021)

753. Impact of COVID-19 on Healthcare Facility-Onset Clostridiodes difficile Infection
por: Suleyman, Geehan, et al.
Publicado: (2021)

749. A Nurse-Driven Protocol for Early Detection of Clostridiodes difficile Infections
por: Beckman, Shannon, et al.
Publicado: (2021)

The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic
por: Mason, Clive S., et al.
Publicado: (2023)

708. Three Stages of Laboratory Stewardship in Improving Appropriate Clostridiodes Difficile Testing
por: Beckman, Shannon, et al.
Publicado: (2023)

Identification of ADS024, a newly characterized strain of Bacillus velezensis with direct Clostridiodes difficile killing and toxin degradation bio-activities
por: O’Donnell, Michelle M., et al.
Publicado: (2022)

Two Groups of Cocirculating, Epidemic Clostridiodes difficile Strains Microdiversify through Different Mechanisms
por: Murillo, Tatiana, et al.
Publicado: (2018)

Clostridiodes difficile in COVID-19 Patients, Detroit, Michigan, USA, March–April 2020
por: Lakkasani, Saraswathi, et al.
Publicado: (2020)

2346. Cost Savings Associated with Implementation of Clinical Decision Support for Clostridiodes difficile Testing
por: Hoegg, Cindy L, et al.
Publicado: (2019)

Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review
por: Gupta, Akshita, et al.
Publicado: (2021)

Rate and predictors of 30-day readmission for clostridiodes difficile: a United States analysis
por: Kichloo, Asim, et al.
Publicado: (2022)

670. Clinical Characteristics and Outcomes in Patients with Healthcare Facility-Onset Clostridiodes difficile Infections
por: Joshi, Seema, et al.
Publicado: (2023)

Rational design of a microbial consortium of mucosal sugar utilizers reduces Clostridiodes difficile colonization
por: Pereira, Fátima C., et al.
Publicado: (2020)

2424. Shedding of Viable Clostridiodes difficile in Patients Admitted to a Medical Intensive Care Unit
por: Young, Vincent B, et al.
Publicado: (2019)

In veteran outpatients, antibiotics remain significant risk factor for community-acquired Clostridiodes difficile infection
por: Akpoji, Ukwen, et al.
Publicado: (2022)

Evidence of within-facility patient–patient Clostridiodes difficile infection spread across diverse settings
por: Justice, Samuel, et al.
Publicado: (2022)

The real efficacy of microbiota restoration following standard of care antimicrobial in patients with recurrent Clostridiodes difficile
por: Sehgal, Kanika, et al.
Publicado: (2023)

Clinical Characteristics and Fecal Microbiome in Recurrent Versus Nonrecurrent Clostridioides difficile Infection
por: Lanjewar, Swapnil, et al.
Publicado: (2021)

Multiplex Immunoassay Techniques for On-Site Detection of Security Sensitive Toxins
por: Pöhlmann, Christopher, et al.
Publicado: (2020)

The Association Between the Frequency of Interruptions in Antibiotic Exposure and the Risk of Health Care-Associated Clostridiodes difficile Infection
por: Song, Jiyoun, et al.
Publicado: (2020)

706. Effect of the Covid-19 Pandemic on Rates of Recurrent Clostridiodes difficile Infection in the Veterans Affairs System
por: Drekonja, Dimitri M, et al.
Publicado: (2021)

Engineered Secretory Immunoglobulin A provides insights on antibody-based effector mechanisms targeting Clostridiodes difficile
por: Bharathkar, Sonya Kumar, et al.
Publicado: (2023)

798. Metronidazole Exposure Prior to Clostridiodes difficile Infection (CDI) is a Risk Factor for Severe C. difficile Disease in Cancer Patients
por: Francisco, Denise Marie A, et al.
Publicado: (2020)

Development of an Ultrasensitive Immunoassay for Detecting Tartrazine
por: Li, Zhuokun, et al.
Publicado: (2013)

675. The Fidaxomicin Cascade: Analysis of Success Rates and Barriers of Fidaxomicin Discharge Prescriptions for Inpatients Diagnosed with Clostridiodes Difficile
por: Cook, Ellen, et al.
Publicado: (2023)

Ultrasensitive multiplexed immunoassay of autophagic biomarkers based on Au/rGO and Au nanocages amplifying electrochemcial signal
por: Wang, Guannan, et al.
Publicado: (2017)

Development and Validation of an Ultrasensitive Procalcitonin Sandwich Immunoassay
por: Carcamo Yañez, Viviana A., et al.
Publicado: (2017)

1093. Single Molecule Counting Technology for Ultrasensitive Quantification of Clostridium difficile Toxins A and B
por: Katzenbach, Phoebe, et al.
Publicado: (2018)

645. Absence of Toxemia in Clostridioides difficile infection: Results from Ultrasensitive Toxin Assay of Serum
por: Sprague, Rebecca, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2n7rnpsrt7pl2dju5191lak96n